Dual inhibition of p38α MAPK and Casein kinase δ/ε as a novel treatment strategy for AR-independent and taxane-resistant advanced prostate cancer
The results suggest that TAK-715 treatment has the potential to decrease oncogenic progression and cancer stem cell-like activity in drug-resistant, aggressive, and stem-like mCRPC cells.